Suvonstobart Biosimilar Monoclonal Antibody (CD24) for Research

Cat No.: GMP-Bios-INN-1404

Anti-CD24 therapeutic antibody (Pre-made Suvonstobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Suvonstobart (development code IMM-47) is a humanized monoclonal antibody targeting CD24. It is developed by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. for Oncology in Phase I development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1404-1mg 1mg 3090
GMP-Bios-INN-1404-10mg 10mg
GMP-Bios-INN-1404-100mg 100mg
GMP-Bios-INN-1404-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Suvonstobart biosimilar, Whole mAb, Anti-CD24 Antibody: Anti-CD24/Signal transducer CD24/Small cell lung carcinoma cluster 4 antigen/CD24A therapeutic antibody
INN Name Suvonstobart
Target CD24
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC